Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer

Nutrition Reviews

Volumn 68, Issue 9, 2010, Pages 542-555

  De Souza, Paul L ^a   Russell, Pamela J ^b   Kearsley, John H ^c   Howes, Laurence G ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Translational Research Institute   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

Chemoprevention; Clinical trials; Daidzein; Equol; Genistein; Phenoxodiol; Signal transduction

Indexed keywords

AGLYCONE; ANTHOCYANIN; BETA GLUCOSIDASE; BETA LAPACHONE; BICALUTAMIDE; BIOCHANIN A; CALCITRIOL; CASPASE; CATECHIN; CHALCONE; CISPLATIN; DAIDZEIN; DOCETAXEL; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; FOCAL ADHESION KINASE; GENISTEIN; GLYCITEIN; ISOFLAVONE; LIGNAN; LINOLEIC ACID; LIPOPROTEIN LIPASE; PACLITAXEL; PERIFOSINE; PHENOXODIOL; PROSTATE SPECIFIC ANTIGEN; RED CLOVER EXTRACT; SOYBEAN PROTEIN; THEARUBIGIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASIA; BIOAVAILABILITY; BREAST TENDERNESS; CANCER CELL; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CHEMICAL STRUCTURE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONJUGATION; CONTINUOUS INFUSION; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FOOT EDEMA; FRUIT; GASTROINTESTINAL ABSORPTION; HERB; HUMAN; HYDROLYSIS; HYPOPHOSPHATEMIA; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INGESTION; INTERVENTION STUDY; INTESTINE FLORA; KIDNEY CANCER; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NAUSEA; NEUTROPENIA; PHARMACOGENOMICS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RASH; RED CLOVER; REVIEW; RISK BENEFIT ANALYSIS; RYE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOYBEAN; STEADY STATE; VEGETABLE; VOMITING; WESTERN HEMISPHERE; XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CHEMOPREVENTION; HUMANS; ISOFLAVONES; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77956632483     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2010.00314.x     Document Type: Review

References (163)

1. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol. 2002;3:364-373.
2. Castle EP, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Urol Clin North Am. 2002;29:71-81, viii-ix.
3. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005;23:8152-8160.
4. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int. 2006;89:1121-1134.
5. Von Low EC, Perabo FG, Siener R, Muller SC. Facts and fiction of phytotherapy for prostate cancer: A critical assessment of preclinical and clinical data. In Vivo. 2007;21:189-204.
6. Jian L. Soy, isoflavones, and prostate cancer. Mol Nutr Food Res. 2009;53:217-226.
7. Anderson JW, Smith BM, Washnock CS. Cardiovascular and renal benefits of dry bean and soybean intake. Am J Clin Nutr. 1999;70(Suppl 3):S464-S474.
8. Franke AA, Custer LJ, Cerna CM, Narala K. Rapid HPLC analysis of dietary phytoestrogens from legumes and from human urine. Proc Soc Exp Biol Med. 1995;208:18-26.
9. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. 2006;55:1-12.
10. Hur HG, Lay JO, Jr, Beger RD, Freeman JP, Rafii F. Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. Arch Microbiol. 2000;174:422-428.
11. Zubik L, Meydani M. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am J Clin Nutr. 2003;77:1459-1465.
12. Setchell KD, Brown NM, Zimmer-Nechemias L, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr. 2002;76:447-453.
13. Yuan JP, Wang JH, Liu X. Metabolism of dietary soy isoflavones to equol by human intestinal microflora - implications for health. Mol Nutr Food Res. 2007;51:765-781.
14. Wiseman H, Casey K, Bowey EA, et al. Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults. Am J Clin Nutr. 2004;80:692-699.
15. Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers between prostate cancer patients and controls: Case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004;34:86-89.
16. Hedlund TE, Maroni PD, Ferucci PG, et al. Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr. 2005;135:1400-1406.
17. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: Exploring the relevance to human health. Exp Biol Med (Maywood). 2005;230:155-170.
18. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252-4263.
19. McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA. 2010; 107:3123-3128.
20. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2003;54:68-78.
21. Wiseman H. The therapeutic potential of phytoestrogens. Expert Opin Investig Drugs. 2000;9:1829-1840.
22. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genisteininduced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol. 1997;51:193-200.
23. Zhang YC, Albrecht D, Bomser J, Schwartz SJ, Vodovotz Y. Isoflavone profile and biological activity of soy bread. J Agric Food Chem. 2003;51:7611-7616.
24. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008;269:226-242.
25. Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. Clin Exp Metastasis. 1996;14:389-398.
26. Liu Y, Kyle E, Lieberman R, Crowell J, Kellof G, Bergan RC. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation. Clin Exp Metastasis. 2000;18:203-212.
27. Agarwal C, Sharma Y, Agarwal R. Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: Modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. Mol Carcinog. 2000;28:129-138.
28. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000;60:1051-1059.
29. Shen JC, Klein RD, Wei Q, et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog. 2000;29:92-102.
30. Suzuki K, Koike H,Matsui H, et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer. 2002;99:846-852.
31. Gao S, Liu GZ, Wang Z. Modulation of androgen receptordependent transcription by resveratrol and genistein in prostate cancer cells. Prostate. 2004;59:214-225.
32. Yu L, Blackburn GL, Zhou JR. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr. 2003;133:389-392.
33. Bylund A, Zhang JX, Bergh A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate. 2000;42:304-314.
34. Rice L, Samedi VG, Medrano TA, et al. Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. Prostate. 2002;52:201-212.
35. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001;61: 6777-6782.
36. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr. 2005;135:989-995.
37. Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund- Wistar rats. Cancer Lett. 2002;186:11-18.
38. Kato K, Takahashi S, Cui L, et al. Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. Jpn J Cancer Res. 2000;91:786-791.
39. McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr Cancer. 2007;57:184-193.
40. Aronson WJ, Tymchuk CN, Elashoff RM, et al. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer. 1999;35:130-136.
41. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129:1628-1635.
42. Zhou JR, Yu L, Zhong Y, et al. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate. 2002;53:143-153.
43. Cohen LA, Zhao Z, Pittman B, Scimeca J. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate. 2003;54:169-180.
44. McEnteeMF, Ziegler C, Reel D, et al. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. Am J Pathol. 2008;173:229-241.
45. Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, Ma J. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:1364-1370. (Pubitemid 47076865)
46. Kelley NS, Hubbard NE, Erickson KL. Conjugated linoleic acid isomers and cancer. J Nutr. 2007;137:2599-2607.
47. Ping SY, Hour TC, Lin SR, Yu DS. Taxol synergizes with antioxidants in inhibiting hormal refractory prostate cancer cell growth. Urol Oncol. 2010;28:170-179.
48. Raffoul JJ, Banerjee S, Che M, et al. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer. 2007;120:2491-2498.
49. Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25- dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol. 2005;241:49-61.
50. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, Jr, de Vere White RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007;13:6204-6216.
51. Burich RA, Holland WS, Vinall RL, Tepper C, White RW, Mack PC. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and -independent prostate cancer cell lines. BJU Int. 2008;102:1458-1466.
52. Kumi-Diaka J. Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and betalapachone. Biol Cell. 2002;94:37-44.
53. Sakamoto K. Synergistic effects of thearubigin and genistein on human prostate tumor cell (PC-3) growth via cell cycle arrest. Cancer Lett. 2000;151:103-109.
54. McPherson RA, Galettis PT, de Souza PL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br J Cancer. 2009;100:649-655.
55. Wang Y, Raffoul JJ, Che M, et al. Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res. 2006;166:(Pt 1):73-80.
56. Naik HR, Lehr JE, Pienta KJ. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Anticancer Res. 1994;14:2617-2619.
57. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate. 1993;22:335-345.
58. Adlercreutz H. Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest. 1990;201:3-23.
59. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12:665-668.
60. Ozasa K, Nakao M,Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004;95:65-71.
61. Ozasa K, Nakao M, Watanabe Y, et al. Association of serum phytoestrogen concentration and dietary habits in a sample set of the JACC Study. J Epidemiol. 2005;15(Suppl 2):S196-S202. (Pubitemid 41410104)
62. Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: The Japan Public Health Center. J Clin Oncol. 2008;26:5923-5929.
63. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998;9:553-557.
64. Nagata Y, Sonoda T, Mori M, et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007;137:1974-1979.
65. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007;16:538-545. (Pubitemid 46548658)
66. Wong SY, Lau WW, Leung PC, Leung JC, Woo J. The association between isoflavone and lower urinary tract symptoms in elderly men. Br J Nutr. 2007;98:1237-1242.
67. Venkitaraman R, Thomas K, Grace P, et al. Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. Int J Biol Markers. 2008;23:192-197.
68. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: A revisit of a meta-analysis. Am J Clin Nutr. 2009;89:1155-1163.
69. Hedlund TE, van Bokhoven A, Johannes WU, Nordeen SK, Ogden LG. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2006;66:557-566.
70. Brossner C, Petritsch K, Fink K, et al. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology. 2004;64:707-711.
71. Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE. Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr. 2007;98:388-396.
72. Rannikko A, Petas A, Rannikko S, Adlercreutz H. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation. Prostate. 2006;66:82-87. (Pubitemid 43005951)
73. Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate. 2009;69:719-726.
74. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131(Suppl 4):S1362-S1375.
75. Richelle M, Pridmore-Merten S, Bodenstab S, Enslen M, Offord EA. Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women. J Nutr. 2002;132:2587-2592.
76. Setchell KD, Faughnan MS, Avades T, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr. 2003;77:411-419.
77. Howes J,Waring M, Huang L, Howes LG. Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense). J Altern Complement Med. 2002;8:135-142.
78. Rufer CE, Bub A, Moseneder J, Winterhalter P, Sturtz M, Kulling SE. Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: A randomized, double-blind, crossover study. Am J Clin Nutr. 2008;87: 1314-1323.
79. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: Single-dose administration to healthy men. Am J Clin Nutr. 2002;75:126-136.
80. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. Safety and pharmacokinetics of purified soy isoflavones: Single-dose administration to postmenopausal women. Am J Clin Nutr. 2002;76:1126-1137.
81. Lu LJ, Anderson KE. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Am J Clin Nutr. 1998;68(Suppl 6):S1500-S1504.
82. King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr. 1998;67:867-872.
83. Takimoto CH, Glover K, Huang X, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:(Pt 1):1213-1221.
84. Li Z, Aronson WJ, Arteaga JR, et al. Feasibility of a low-fat/ high-fiber diet intervention with soy supplementation in prostate cancer patients after prostatectomy. Eur J Clin Nutr. 2008;62:526-536.
85. Akaza H, Miyanaga N, Takashima N, et al. Is daidzein non-metabolizer a high risk for prostate cancer? A casecontrolled study of serum soybean isoflavone concentration. Jpn J Clin Oncol. 2002;32:296-300.
86. Low YL, Taylor JI, Grace PB, et al. Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men. J Nutr. 2005;135:2680-2686.
87. Steiner C, Arnould S, Scalbert A, Manach C. Isoflavones and the prevention of breast and prostate cancer: New perspectives opened by nutrigenomics. Br J Nutr. 2008;99E:(Suppl 1):ES78-E108.
88. Xiang H, Schevzov G, Gunning P, Williams HM, Silink M. A comparative study of growth-inhibitory effects of isoflavones and their metabolites on human breast and prostate cancer cell lines. Nutr Cancer. 2002;42:224-232.
89. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59:141-147.
90. Pendleton JM, Tan WW, Anai S, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008;8:132.
91. Maskarinec G, Morimoto Y, Hebshi S, Sharma S, Franke AA, Stanczyk FZ. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr. 2006;60:1423-1429.
92. Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2003;47:111-117.
93. Dalais FS, Meliala A,Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology. 2004;64:510-515.
94. Jenkins DJ, Kendall CW, D'Costa MA, et al. Soy consumption and phytoestrogens: Effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. J Urol. 2003;169:507-511.
95. Adams KF, Chen C, Newton KM, Potter JD, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2004;13:644-648.
96. Urban D, Irwin W, Kirk M, et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol. 2001;165:294-300.
97. Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol. 2000;16:1091-1097.
98. Habito RC, Montalto J, Leslie E, Ball MJ. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males. Br J Nutr. 2000;84:557-563.
99. Allen NE, Appleby PN, Davey GK, Key TJ. Soy milk intake in relation to serum sex hormone levels in British men. Nutr Cancer. 2001;41:41-46.
100. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: Multiple-dose administration to men with prostate neoplasia. Nutr Cancer. 2004;48:160-170.
101. Brown DM, Kelly GE, Husband AJ. Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol Biotechnol. 2005;30:253-270.
102. Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006;17:860-865.
103. de Souza PL, Liauw W, Links M, Pirabhahar S, Kelly G, Howes LG. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemother Pharmacol. 2006;58:427-433.
104. Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: Current evidence for a role in breast and prostate cancer. Br J Nutr. 2004;91:513-531.
105. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592-5595.
106. Cao F, Jin TY, Zhou YF. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed Environ Sci. 2006;19:35-41.
107. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res. 2002;8:2369-2377.
108. El Touny LH, Banerjee PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis. 2007;28:1710-1717.
109. Park SS, KimYN, Jeon YK, et al. Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma. Cancer Chemother Pharmacol. 2005;56:271-278.
110. Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res. 2004;10:5282-5292.
111. Tepper CG, Vinall RL, Wee CB, et al. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007;67:521-535.
112. Xu L, Bergan RC. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Mol Pharmacol. 2006;70:869-877.
113. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 2005;65:3470-3478.
114. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate. 2001;46:98-107.
115. Wang X, Clubbs EA, Bomser JA. Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. J Nutr Biochem. 2006;17:204-210.
116. Wang J, Eltoum IE, Lamartiniere CA. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol Cell Endocrinol. 2004;219:171-180.
117. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V, Kong AN. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch Pharm Res. 2006;29:633-644.
118. Clubbs EA, Bomser JA. Glycitein activates extracellular signal-regulated kinase via vascular endothelial growth factor receptor signaling in nontumorigenic (RWPE-1) prostate epithelial cells. J Nutr Biochem. 2007;18:525-532.
119. Lazarevic B, Karlsen SJ, Saatcioglu F. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep. 2008;19:1231-1235.
120. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 1999; 35:167-174.
121. Raffoul JJ, Banerjee S, Singh-Gupta V, et al. Downregulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res. 2007;67:2141-2149.
122. Singh-Gupta V, Zhang H, Banerjee S, et al. Radiationinduced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer. 2009;124:1675-1684.
123. Takahashi Y, Lavigne JA, Hursting SD, et al. Molecular signatures of soy-derived phytochemicals in androgenresponsive prostate cancer cells: A comparison study using DNA microarray. Mol Carcinog. 2006;45:943-956.
124. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr. 2003;133:2367-2376.
125. Pinski J, Wang Q, Quek ML, et al. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate. 2006;66:1136-1143. (Pubitemid 44175336)
126. Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 2005;65:8200-8208.
127. Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003;66:965-976.
128. Li X, Marani M, Mannucci R, et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. 2001;61:1699-1706.
129. Alvero AB, O'Malley D, Brown D, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer. 2006;106:599-608.
130. Herst PM, Petersen T, Jerram P, Baty J, Berridge MV. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007;74:1587-1595.
131. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003;22:2611-2620.
132. Kluger HM, McCarthy MM, Alvero AB, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med. 2007;5:6.
133. Sapi E, Alvero AB, Chen W, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res. 2004;14:567-578.
134. Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53- independent induction of p21WAF1/CIP1. Cancer Res. 2005;65:3364-3373.
135. Choueiri TK,Wesolowski R, Mekhail TM. Phenoxodiol: Isoflavone analog with antineoplastic activity. Curr Oncol Rep. 2006;8:104-107.
136. Kumi-Diaka J, Butler A. Caspase-3 protease activation during the process of genistein-induced apoptosis in TM4 testicular cells. Biol Cell. 2000;92:115-124.
137. Kumi-Diaka J, Sanderson NA, Hall A. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell. 2000;92:595-604.
138. Li Y, Sarkar FH. Gene expression profiles of genisteintreated PC3 prostate cancer cells. J Nutr. 2002;132:3623-3631.
139. Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem. 2007;18:408-417.
140. Booth NL, Overk CR, Yao P, et al. The chemical and biologic profile of a red clover (Trifolium pratense L.) phase II clinical extract. J Altern Complement Med. 2006;12:133-139.
141. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999;18:4608-4618.
142. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alphareductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995;147:295-302.
143. Takahashi Y, Hursting SD, Perkins SN, Wang TC, Wang TT. Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol Carcinog. 2006;45:18-25.
144. Rice L, Handayani R, Cui Y, et al. Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. J Nutr. 2007;137:964-972.
145. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998;32:123-131.
146. Touny LH, Banerjee PP. Identification of both Myt-1 and Wee-1 as necessarymediators of the p21-independent inactivation of the cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein. Prostate. 2006;66:1542-1555.
147. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer. 1998;31:184-191. (Pubitemid 28481852)
148. Li Y, Sarkar FH. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 2002;186:157-164.
149. Kumi-Diaka JK, Hassanhi M, Merchant K, Horman V. Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells. J Med Food. 2006;9: 491-497.
150. Gamble JR, Xia P, Hahn CN, et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer. 2006;118:2412-2420.
151. Swami S, Krishnan AV, Moreno J, et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer. 2008;124:2050-2059.
152. Davies SL, Bozzo J. Spotlight on tNOX: A tumor-selective target for cancer therapies. Drug News Perspect. 2006;19:223-225.
153. De Luca T, Morre DM, Zhao H, Morre DJ. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1- phosphate levels accompanying G1 arrest and apoptosis. BioFactors. 2005;25:43-60.
154. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr. 2007;137(Suppl 1):223S-228S.
155. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005;11:(Pt 1):7033-7041.
156. Skogseth H, Larsson E, Halgunset J. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells. Apmis. 2005;113:332-339.
157. Jarred RA, Keikha M, Dowling C, et al. Induction of apoptosis in lowtomoderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev. 2002;11:1689-1696.
158. deVereWhite RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology. 2004;63:259-263.
159. Schroder FH, Roobol MJ, Boeve ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: Effectiveness of a dietary supplement. Eur Urol. 2005;48:922-930.
160. Rannikko A, Petas A, Raivio T, Janne OA, Rannikko S, Adlercreutz H. The effects of short-term oral phytoestrogen supplementation on the hypothalamic-pituitary-testicular axis in prostate cancer patients. Prostate. 2006;66:1086-1091. (Pubitemid 43939213)
161. Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2007;59:1-7.
162. Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, Kurzer MS. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr. 2007;137:1769-1775.
163. Kumar NB, Krischer JP, Allen K, et al. Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007;59:163-168.